Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 10/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.53 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | NSD2 | O96028 | 2/20 | 0.43 |
| ▸ | LIG1 | P18858 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 3/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892415 | 0.80 | CES1 (0.67) | CES1ALDH1A1ALDH2ALDH3A1DAO | |
| SCHEMBL2373643 | 0.77 | CES1 (0.47) | CES1ALDH1A1ALDH2ALDH3A1DAO | |
| SCHEMBL16647187 | 0.77 | CES1 (0.67) | CES1ALDH1A1ALDH2ALDH3A1DAO | |
| SCHEMBL29689346 | 0.77 | CES1 (0.62) | CES1ALDH1A1ALDH2ALDH3A1DAO | |
| SCHEMBL3085898 | 0.77 | CES1 (0.62) | CES1ALDH1A1ALDH2ALDH3A1DAO | |
| SCHEMBL951629 | 0.77 | CES1 (1.00) | CES1ALDH1A1ALDH2ALDH3A1DAO | |
| SCHEMBL3096093 | 0.77 | DAO (0.56) | CES1ALDH1A1ALDH2ALDH3A1DAO | |
| SCHEMBL16108402 | 0.77 | CES1 (0.45) | CES1ALDH1A1ALDH2ALDH3A1DAO | |
| SCHEMBL30498292 | 0.77 | CES1 (0.45) | CES1ALDH1A1ALDH2ALDH3A1DAO | |
| SCHEMBL21777132 | 0.74 | HPGD (0.39) | CES1ALDH1A1ALDH2ALDH3A1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007511607-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1706129-A1 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2006-10-04 | — | — | EP | claimed |
| WO-2005049064-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-06-02 | — | — | WO | claimed |
| US-12404250-B2 | PARP inhibitors for treating cancer and asthma | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240409518-A1 | PARP INHIBITORS FOR TREATING CANCER AND ASTHMA | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-12-12 | — | — | US | disclosed |
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-12030858-B2 | PARP inhibitors for treating cancer and asthma | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030858-B2 | PARP inhibitors for treating cancer and asthma | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030858-B2 | PARP inhibitors for treating cancer and asthma | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2024-05-02 | — | — | US | disclosed |
| EP-3843726-B1 | PARP INHIBITORS FOR TREATING CANCER AND ASTHMA | UNIV OREGON HEALTH & SCIENCE (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-1931205-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20080044401-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-02-21 | — | — | US | disclosed |
| US-7265093-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-09-04 | — | — | US | disclosed |
| WO-2007025247-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1706129-A1 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-03-09 | — | — | US | disclosed |
| WO-2005049064-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | disclosed |
| US-6586447-B1 | 3,3-disubstituted-oxindole derivatives useful as anticancer agents | PFIZER INC | 2003-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044401-A1 | DRUG THERAPY FOR CELIAC SPRUE | SI, DNPEP, SPINT2 | CES1 688/4885ALDH1A1 3795/4885ALDH2 4343/4885 |
| US-12404250-B2 | PARP inhibitors for treating cancer and asthma | PARP1, PARP2, PARP11 | CES1 2754/4885ALDH1A1 748/4885ALDH2 796/4885 |
| US-12030858-B2 | PARP inhibitors for treating cancer and asthma | PARP1, PARP2, PARP11 | CES1 2754/4885ALDH1A1 748/4885ALDH2 796/4885 |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | KRAS, NRAS, G3BP1 | CES1 2649/4885ALDH1A1 3389/4885ALDH2 4286/4885 |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | MGMT, GMFG, HNMT | CES1 346/4885ALDH1A1 1608/4885ALDH2 1634/4885 |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | SI, DNPEP, SPINT2 | CES1 688/4885ALDH1A1 3795/4885ALDH2 4343/4885 |
| US-20240409518-A1 | PARP INHIBITORS FOR TREATING CANCER AND ASTHMA | PARP1, PARP2, PARP11 | CES1 2754/4885ALDH1A1 748/4885ALDH2 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.